BOSTON--(BUSINESS WIRE)--NMT Medical, Inc. (NASDAQ: NMTI) today announced that the first patients have been randomized in its pivotal patent foramen ovale (PFO)/migraine trial in the United States, MIST II. The MIST II trial is designed to evaluate the safety and effectiveness of NMT’s BioSTAR® implant technology for the treatment and prevention of migraine headaches in patients with PFO. The randomization took place at the Swedish Medical Center in Seattle, Washington. The trial currently is being conducted at more than 25 sites across the country.
